Abstract
The objectives of this pilot study are to evaluate the feasibility and safety of
intramyocardial injection of autologous c-kit+ cells during the Stage II BDCPA operation and
to observe effects on clinical outcome including right ventricular myocardial function,
severity of tricuspid regurgitation, incidence of serious adverse events,
re-hospitalizations, changes in health status, the need for transplantation, or mortality.
